Tag: Allogeneic
Mallinckrodt’s Cryopreserved StrataGraft Makes Phase III Progress Treating Thermal Burns
Mallinckrodt plc, a global biopharmaceutical company, has
announced positive top-line results from its pivotal Phase 3 clinical trial of
its investigational StrataGraft® regenerative tissue. The study, which met both
primary endpoints, evaluated the efficacy and safety of a single application of
StrataGraft in...
Grünenthal And Mesoblast Partner To Develop Allogeneic Cell Therapy For Chronic Low Back Pain
Grünenthal, a global leader in pain management, and
Mesoblast Limited, a world leader in allogeneic cellular medicines for
inflammatory diseases, have entered into a strategic partnership to develop and
commercialise MPC-06-ID, a Phase III allogeneic cell therapy candidate for the
treatment of chronic...
FDA Grants RMAT Designation To Cellerant’s “Off-The-Shelf” Romyelocel-L Cell Therapy
Cellerant Therapeutics Inc., is a clinical-stage company developing innovative cell and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s romyelocel-L (human myeloid progenitor cells) “off-the-shelf” cell therapy does not require HLA matching and is designed to prevent...
